thiotepa has been researched along with Diffuse Large B-Cell Lymphoma in 29 studies
Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thiotepa is a common alkylating agent known to precipitate cutaneous reactions consistent with toxic erythema of chemotherapy, including erythema and hyperpigmentation." | 7.96 | Thiotepa hyperpigmentation preceding epidermal necrosis: malignant intertrigo misdiagnosed as Stevens-Johnson syndrome-toxic epidermal necrolysis overlap. ( Choate, EA; Sarantopoulos, GP; Truong, AK; Worswick, SD, 2020) |
| "Thiotepa is a common alkylating agent known to precipitate cutaneous reactions consistent with toxic erythema of chemotherapy, including erythema and hyperpigmentation." | 3.96 | Thiotepa hyperpigmentation preceding epidermal necrosis: malignant intertrigo misdiagnosed as Stevens-Johnson syndrome-toxic epidermal necrolysis overlap. ( Choate, EA; Sarantopoulos, GP; Truong, AK; Worswick, SD, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (37.93) | 18.7374 |
| 1990's | 2 (6.90) | 18.2507 |
| 2000's | 6 (20.69) | 29.6817 |
| 2010's | 3 (10.34) | 24.3611 |
| 2020's | 7 (24.14) | 2.80 |
| Authors | Studies |
|---|---|
| Puckrin, R | 1 |
| Chua, N | 1 |
| Shafey, M | 1 |
| Stewart, DA | 1 |
| Wendler, J | 1 |
| Fox, CP | 2 |
| Valk, E | 1 |
| Steinheber, C | 1 |
| Fricker, H | 1 |
| Isbell, LK | 1 |
| Neumaier, S | 1 |
| Okosun, J | 1 |
| Scherer, F | 1 |
| Ihorst, G | 1 |
| Cwynarski, K | 3 |
| Schorb, E | 2 |
| Illerhaus, G | 2 |
| Kodama, Y | 1 |
| Saburi, M | 1 |
| Maruyama, R | 1 |
| Sakata, M | 1 |
| Takata, H | 1 |
| Miyazaki, Y | 1 |
| Kawano, K | 1 |
| Wada, J | 1 |
| Urabe, S | 1 |
| Hazuku, T | 1 |
| Ohtsuka, E | 1 |
| Arshad, S | 1 |
| Fang, X | 1 |
| Ahn, KW | 1 |
| Kaur, M | 1 |
| Scordo, M | 1 |
| Sauter, CS | 1 |
| Furqan, F | 1 |
| Awan, FT | 1 |
| Hamadani, M | 1 |
| Alderuccio, JP | 1 |
| Nayak, L | 1 |
| Kasenda, B | 1 |
| Linton, K | 1 |
| Martinez-Calle, N | 1 |
| Calimeri, T | 1 |
| Ninkovic, S | 1 |
| Eyre, TA | 1 |
| Cummin, T | 1 |
| Smith, J | 1 |
| Yallop, D | 1 |
| De Marco, B | 1 |
| Krampera, M | 1 |
| Trefz, S | 1 |
| Orsucci, L | 1 |
| Fabbri, A | 1 |
| Ferreri, AJM | 1 |
| Choate, EA | 1 |
| Sarantopoulos, GP | 1 |
| Worswick, SD | 1 |
| Truong, AK | 1 |
| Lee, MY | 1 |
| Kim, HS | 1 |
| Lee, JY | 1 |
| Lim, SH | 1 |
| Kang, ES | 1 |
| Ko, YH | 1 |
| Kim, SJ | 1 |
| Kim, WS | 1 |
| Miura, Y | 1 |
| Toyooka, N | 1 |
| Iwai, F | 1 |
| Matsui, Y | 1 |
| Hirai, M | 1 |
| Kaneko, H | 1 |
| Watanabe, M | 1 |
| Tsudo, M | 1 |
| Papageorgiou, SG | 1 |
| Diamantopoulos, P | 1 |
| Levidou, G | 1 |
| Angelopoulou, MK | 1 |
| Economopoulou, P | 1 |
| Efthimiou, A | 1 |
| Constantinou, N | 1 |
| Katsigiannis, A | 1 |
| Korkolopoulou, P | 1 |
| Pappa, V | 1 |
| Economopoulou, C | 1 |
| Georgiou, G | 1 |
| Dimou, M | 1 |
| Tsirigotis, P | 1 |
| Kyrtsonis, MC | 1 |
| Kotsianidis, I | 1 |
| Kalpadakis, C | 1 |
| Dimopoulos, MA | 1 |
| Beris, P | 1 |
| Meletis, J | 1 |
| Pangalis, GA | 1 |
| Dervenoulas, J | 1 |
| Panayiotidis, P | 1 |
| Vassilakopoulos, TP | 1 |
| ISRAELS, MC | 2 |
| LEONARD, BJ | 2 |
| WILKINSON, JF | 2 |
| IAKUBCHIK, FM | 1 |
| BRINDLEY, CO | 1 |
| PRAETORIUS, E | 1 |
| BOURDIN, JS | 1 |
| SARACINO, RT | 1 |
| LILLE, I | 1 |
| GABAY, F | 1 |
| COSTAKEL, O | 1 |
| KADYROV, FA | 1 |
| Soussain, C | 3 |
| Hoang-Xuan, K | 3 |
| Levy, V | 2 |
| Stern, BV | 1 |
| Baehring, JM | 1 |
| Kleopa, KA | 1 |
| Hochberg, FH | 1 |
| Taillandier, L | 1 |
| Fourme, E | 1 |
| Choquet, S | 1 |
| Witz, F | 1 |
| Casasnovas, O | 1 |
| Dupriez, B | 1 |
| Souleau, B | 1 |
| Taksin, AL | 1 |
| Gisselbrecht, C | 1 |
| Jaccard, A | 1 |
| Omuro, A | 1 |
| Sanson, M | 1 |
| Janvier, M | 1 |
| Kolb, B | 1 |
| Zini, JM | 1 |
| Leblond, V | 2 |
| Tarella, C | 1 |
| Zanni, M | 1 |
| Magni, M | 1 |
| Benedetti, F | 1 |
| Patti, C | 1 |
| Barbui, T | 1 |
| Pileri, A | 1 |
| Boccadoro, M | 1 |
| Ciceri, F | 1 |
| Gallamini, A | 1 |
| Cortelazzo, S | 1 |
| Majolino, I | 1 |
| Mirto, S | 1 |
| Corradini, P | 1 |
| Passera, R | 1 |
| Pizzolo, G | 1 |
| Gianni, AM | 1 |
| Rambaldi, A | 1 |
| Sandor, V | 1 |
| Stark-Vancs, V | 1 |
| Pearson, D | 1 |
| Nussenblat, R | 1 |
| Whitcup, SM | 1 |
| Brouwers, P | 1 |
| Patronas, N | 1 |
| Heiss, J | 1 |
| Jaffe, E | 1 |
| deSmet, M | 1 |
| Kohler, D | 1 |
| Simon, R | 1 |
| Wittes, R | 1 |
| Suzan, F | 1 |
| Cassoux, N | 1 |
| Azar, N | 1 |
| Belanger, C | 1 |
| Achour, E | 1 |
| Ribrag, V | 1 |
| Gerber, S | 1 |
| Delattre, JY | 1 |
| Heath, JA | 1 |
| Broxson, EH | 1 |
| Dole, MG | 1 |
| Filippa, DA | 1 |
| George, D | 1 |
| Lyden, D | 1 |
| Dunkel, IJ | 1 |
| Meister, L | 1 |
| Close, P | 1 |
| Ruchelli, E | 1 |
| Gary-Bobo, J | 1 |
| Woenckhaus, HJ | 1 |
| Klemm, D | 1 |
| Obrecht, P | 1 |
| Musaev, KD | 1 |
| Smirnova, IN | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Studio Osservazionale Retrospettivo Multicentrico Sull'Utilizzo di Ibrutinib in Monoterapia o in Associazione a Immunochemioterapia Secondo Schema R-CHOP in Pazienti Adulti Con Diagnosi di PCNSL Ricaduto o Refrattario[NCT05782374] | 36 participants (Anticipated) | Observational | 2022-08-10 | Recruiting | |||
| A Phase 2a Study of the Addition of Temozolomide to a Standard Conditioning Regimen for Autologous Stem Cell Transplantation in Relapsed and Refractory Central Nervous System (CNS) Lymphoma[NCT01235793] | Phase 2 | 11 participants (Actual) | Interventional | 2010-10-14 | Terminated (stopped due to The clinical trial was terminated due to poor enrollment) | ||
| High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial[NCT02531841] | Phase 3 | 250 participants (Anticipated) | Interventional | 2014-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Safety will be assessed using a dose escalation design for temozolomide's use to determine the target dose and also to evaluate any and all acute treatment related toxicities. During the course of patient follow up and therapy, toxicities will be evaluated, particularly as the investigators will be determining the target dose of temozolomide. One of the major criteria for dose limiting toxicity for the study will be any Grade 3 or 4 nonhematologic toxicity from a list of commonly expected toxicities associated with autologous transplantation and temozolomide. (NCT01235793)
Timeframe: One Year
| Intervention | dose in mg/m^2 (Number) |
|---|---|
| DRBEAT Regimen | 773.25 |
"Efficacy of the DRBEAT Regimen will be assessed by analysis of~one-year progression-free survival (PFS), defined as the time interval from maximal response from therapy to tumor regrowth, progression*, or death, (*Progression is defined as meeting the response criteria listed in Table 4: Response Criteria for Primary Central Nervous System Lymphoma according to Abrey LE, Batchelor TT, Ferreri AJM et al.)~and~Overall survival, defined as the time interval between the date of transplant and the date of death from any cause." (NCT01235793)
Timeframe: (1) One Year (2) Until date of death from any cause, assessed up to 2 years
| Intervention | Days (Median) | |
|---|---|---|
| Progression Free Survival | Overall Survival | |
| DRBEAT Regimen | 132 | 564 |
4 trials available for thiotepa and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Optimizing MATRix as remission induction in PCNSL: de-escalated induction treatment in newly diagnosed primary CNS lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Combined Modality | 2022 |
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Combined Mod | 2008 |
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Combined Mod | 2008 |
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Combined Mod | 2008 |
Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Busulfan; Combined Mod | 2008 |
Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Cytar | 1998 |
Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neoplasms; C | 2001 |
25 other studies available for thiotepa and Diffuse Large B-Cell Lymphoma
| Article | Year |
|---|---|
Improving the outcomes of secondary CNS lymphoma with high-dose thiotepa, busulfan, melphalan, rituximab conditioning and autotransplant.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Central Nervous S | 2022 |
[Busulfan/thiotepa followed by autologous peripheral blood stem cell transplantation for refractory diffuse large B-cell lymphoma accompanied by hypopyon].
Topics: Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Doxorubicin; Humans; Lym | 2022 |
Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Central Nervous Syste | 2023 |
How I treat secondary CNS involvement by aggressive lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Humans; Lym | 2023 |
Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Central Nervous Syst | 2020 |
Thiotepa hyperpigmentation preceding epidermal necrosis: malignant intertrigo misdiagnosed as Stevens-Johnson syndrome-toxic epidermal necrolysis overlap.
Topics: Aged; Antineoplastic Agents, Alkylating; Diagnostic Errors; Humans; Hyperpigmentation; Intertrigo; L | 2020 |
Efficacy and feasibility of autologous stem cell transplantation in patients with diffuse large B‑cell lymphoma with secondary central nervous system involvement.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Central Nervous System Neoplas | 2015 |
[Sustained complete remission of intravascular large B-cell lymphoma with recurrent CNS involvement by autologous peripheral blood stem cell transplantation preconditioned with TBC regimen].
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Brain Neop | 2011 |
Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2013 |
Treatment of Hodgkin's granuloma, chronic lymphatic leukaemia, polycythaemia vera, and other reticuloses with triethylenethiophosphoramide.
Topics: Antineoplastic Agents; Hodgkin Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Ce | 1956 |
Treatment of Hodgkin's granuloma, chronic lymphatic leukaemia, polycythaemia vera, and other reticuloses with triethylenethiophosphoramide.
Topics: Antineoplastic Agents; Hodgkin Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Ce | 1956 |
Treatment of Hodgkin's granuloma, chronic lymphatic leukaemia, polycythaemia vera, and other reticuloses with triethylenethiophosphoramide.
Topics: Antineoplastic Agents; Hodgkin Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Ce | 1956 |
Treatment of Hodgkin's granuloma, chronic lymphatic leukaemia, polycythaemia vera, and other reticuloses with triethylenethiophosphoramide.
Topics: Antineoplastic Agents; Hodgkin Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Large B-Ce | 1956 |
[Experience in the use of the preparation thioTEPA in various diseases in children].
Topics: Antineoplastic Agents; Child; Hodgkin Disease; Humans; Infant; Lymphoma, Large B-Cell, Diffuse; Lymp | 1961 |
METHODOLOGY OF PRELIMINARY CHEMOTHERAPEUTIC TRIALS IN PATIENTS WITH MALIGNANT SOLID TUMORS.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Colonic Neoplasms; Cyclophosp | 1963 |
[SURVIVAL TIME AND ABILITY TO WORK IN HEMOBLASTOSES TREATED BY CHEMOTHERAPY].
Topics: Antineoplastic Agents; Aziridines; Biomedical Research; Cyclophosphamide; Genetic Diseases, X-Linked | 1963 |
[STUDY OF VARIATIONS IN THE COMPLEMENT LEVEL IN THE COURSE OF CANCER CHEMOTHERAPY].
Topics: Animals; Breast Neoplasms; Bronchial Neoplasms; Complement System Proteins; Cyclophosphamide; Dexame | 1964 |
THE CHEMOTHERAPY OF CANCER WITH MASSIVE DOSES UNDER THE PROTECTION OF PERFUSION OF AUTOGENOUS HEMATOPOIETIC TISSUE.
Topics: Adenine; Bone Marrow Transplantation; Breast Neoplasms; DNA; Female; Folic Acid; Humans; Lung Neopla | 1964 |
[RETICULOSARCOMA OF THE STOMACH].
Topics: Drug Therapy; Gastrectomy; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasms; Pathol | 1964 |
[Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Central Nervous System Neopla | 2004 |
Multifocal motor neuropathy with conduction block associated with metastatic lymphoma of the nervous system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Demyelinating Diseases; Female; He | 2006 |
Rituximab improves the efficacy of high-dose chemotherapy with autograft for high-risk follicular and diffuse large B-cell lymphoma: a multicenter Gruppo Italiano Terapie Innnovative nei linfomi survey.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplas | 2008 |
Epstein-Barr virus-associated lymphoma in a child undergoing an autologous stem cell rescue.
Topics: Acyclovir; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents, Ph | 2002 |
Granulocytic sarcoma or large cell lymphoma?
Topics: Biopsy; Child, Preschool; Cyclophosphamide; Daunorubicin; Diagnosis, Differential; Etoposide; Female | 1991 |
[Mitomycin alone and in therapeutic association in the palliative treatment of solid tumors].
Topics: Antineoplastic Agents; Breast Neoplasms; Cobalt Isotopes; Cyclophosphamide; Drug Combinations; Femal | 1971 |
[Studies on the lengthening of the survival time of RF mice with retothelial sarcoma by the combination of radiotherapy and chemotherapy].
Topics: Animals; Antineoplastic Agents; Azirines; Lymphoma, Large B-Cell, Diffuse; Mice; Radiation Effects; | 1965 |
[The results of treatment of maxillary sarcomas].
Topics: Adolescent; Adult; Aged; Child; Fibrosarcoma; Giant Cell Tumors; Hemangiosarcoma; Humans; Lymphoma, | 1970 |
[Results of treatment of tonsillar tumors by olivomycin].
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Carcinoma, Squamous Cell; Chlorpromazine; Cyclophosp | 1969 |